Vera Therapeutics (NASDAQ:VERA) Issues Quarterly Earnings Results, Beats Expectations By $0.32 EPS

Vera Therapeutics (NASDAQ:VERA) issued its quarterly earnings data on Thursday. The company reported ($1.30) EPS for the quarter, topping the consensus estimate of ($1.62) by $0.32, FiscalAI reports. The business had revenue of $10.28 million for the quarter, compared to analyst estimates of $3.42 million.

Here are the key takeaways from Vera Therapeutics’ conference call:

• TRUTAKNA showed strong kidney-function results in ORIGIN 3: At 104 weeks, it reduced the risk of kidney disease progression by 76% versus placebo, with kidney-function decline near a physiologic rate. Vera submitted an FDA application seeking full approval and plans an EU application in the first quarter of 2027.
• The early U.S. launch generated about 700 Patient Start Forms since the July approval, and third-quarter product revenue was $10.3 million; management said roughly half the revenue reflected demand and half inventory. The company said prescriptions span patients with both higher and lower proteinuria, while acknowledging that adoption is still at an early stage.
• Interim PIONEER results showed a 52% reduction in proteinuria from baseline at week 24 among 101 adults across broader IgA nephropathy cohorts, including patients with lower kidney function. Results in primary membranous nephropathy were preliminary, based on 16 patients.
• Spending and cash use increased as Vera funded commercialization: third-quarter net loss was $93.7 million, and operating cash use totaled $305.9 million for the first nine months of 2026. The company reported $384 million in cash and marketable securities at quarter-end and borrowed $75 million in October; additional debt capacity is subject to conditions.

Vera Therapeutics Stock Down 5.7%

NASDAQ VERA traded down $1.83 during trading on Thursday, hitting $30.14. The stock had a trading volume of 1,419,234 shares, compared to its average volume of 1,622,788. Vera Therapeutics has a 12 month low of $23.05 and a 12 month high of $56.05. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.92 and a current ratio of 10.92. The company’s 50-day moving average price is $31.83 and its two-hundred day moving average price is $36.84. The company has a market capitalization of $2.17 billion, a PE ratio of -5.14 and a beta of 1.07.

Analysts Set New Price Targets

VERA has been the subject of several recent analyst reports. Leerink Partners initiated coverage on Vera Therapeutics in a report on Monday, October 12th. They issued a “market perform” rating and a $34.00 price target for the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vera Therapeutics in a research report on Friday, October 23rd. TD Cowen reiterated a “buy” rating on shares of Vera Therapeutics in a report on Tuesday, September 15th. Wedbush reiterated a “neutral” rating and issued a $34.00 price objective on shares of Vera Therapeutics in a research report on Monday, August 17th. Finally, Guggenheim increased their target price on Vera Therapeutics from $56.00 to $76.00 and gave the stock a “buy” rating in a research note on Wednesday, July 8th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $76.86.

Insider Buying and Selling at Vera Therapeutics

In other news, CEO Marshall Fordyce sold 18,500 shares of Vera Therapeutics stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $37.00, for a total value of $684,500.00. Following the sale, the chief executive officer directly owned 235,244 shares in the company, valued at $8,704,028. This trade represents a 7.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 15.90% of the stock is owned by corporate insiders.

About Vera Therapeutics

Vera Therapeutics, Inc is a clinical-stage biotechnology company focused on developing treatments for immunological diseases. The company’s research is centered on therapies that target the underlying causes of autoimmune conditions rather than primarily addressing their symptoms.

Vera’s lead product candidate is atacicept, a biologic designed to inhibit the B-cell survival factors BLyS and APRIL. The company has been evaluating atacicept in IgA nephropathy, an autoimmune kidney disease that can lead to progressive loss of kidney function, and has also investigated its potential in other immune-mediated diseases.